Erythropoietin Role in Acute Kidney Injury

• Status: Terminated
• Trial end date: 2021-03-20
• Target enrollment: 0
• Participant gender: All

Summary

The use of erythropoietin to treat anemia in acute kidney injury (AKI) is controversial. No previous clinical trial has assessed the possible reduction of transfusions when erythropoietin is started very early in a setting of in-hospital acute kidney injury.

This randomised multicenter pragmatic clinical trial will compare the need for transfusion in acute kidney injury between two groups: group 1 will receive erythopoietin 4000 UI every other day and group 2 the usual treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saint-Joseph University
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• All adult patients > 18 years old hospitalized with acute kidney injury and anemia

Exclusion Criteria:

• pregnant women, terminally ill patients, patients with major or minor thalassemia, patients with stable chronic kidney disease or patients on dialysis and patients who were receiving rHuEPO or any erythropoiesis-stimulating agent (ESA) before admission.